Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Gain Big on Brigham $BEXP Deal

Several hedge funds gained big Monday after Statoil ASA (STO) announced it was going to buy Brigham Exploration Co. (BEXP) in a $4.4 billion deal. Share price rose from $30.36 at close on Friday to $36.75 at market close Monday. Of the funds we track, the following funds made the most on the news:

Michael Karsch

1. Karsch Capital Management – Michael Karsch: Gained $13.4 million

2. Millennium Management – Israel Englander: Gained $5.1 million

3. Soros Fund Management – George Soros: Gained $2.6 million

4. Clough Capital Partners – Charles Clough: Gained $2.2 million

5. Citadel Investment Group – Ken Griffin: Gained $2.1 million

6. Dawson Capital Management – Jonathan Dawson: Gained $1.9 million

7. Diamondback Capital – Richard Schimel: Gained $1.3 million

8. Marathon Asset Management – Bruce J. Richards And Louis Hanover: Gained $1.2 million

9. Zweig Dimenna Partners – Joe Dimenna: Gained $988,000

10. Copia Capital – Tim Flannery: Gained $903 million

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in BEXP since the end of June. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!